520 related articles for article (PubMed ID: 31339668)
21. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
22. The incremental prognostic and clinical value of multiple novel biomarkers in heart failure.
Jackson CE; Haig C; Welsh P; Dalzell JR; Tsorlalis IK; McConnachie A; Preiss D; Anker SD; Sattar N; Petrie MC; Gardner RS; McMurray JJ
Eur J Heart Fail; 2016 Dec; 18(12):1491-1498. PubMed ID: 27114189
[TBL] [Abstract][Full Text] [Related]
23. Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure.
Porcel JM; Bielsa S; Morales-Rull JL; Civit C; Cao G; Light RW; Esquerda A
Respirology; 2013 Apr; 18(3):540-5. PubMed ID: 23278975
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
25. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure.
Skoglund PH; Arpegård J; Ostergren J; Svensson P
Am J Hypertens; 2014 Mar; 27(3):363-71. PubMed ID: 24470529
[TBL] [Abstract][Full Text] [Related]
26. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure.
Schou M; Gustafsson F; Corell P; Kistorp CN; Kjaer A; Hildebrandt PR
Am Heart J; 2007 Jul; 154(1):123-9. PubMed ID: 17584564
[TBL] [Abstract][Full Text] [Related]
27. Plasma concentrations of novel cardiac biomarkers before and after hemodialysis session.
Mueller T; Gegenhuber A; Kronabethleitner G; Leitner I; Haltmayer M; Dieplinger B
Clin Biochem; 2015 Nov; 48(16-17):1163-6. PubMed ID: 26232288
[TBL] [Abstract][Full Text] [Related]
28. Biomarker guidance allows a more personalized allocation of patients for remote patient management in heart failure: results from the TIM-HF2 trial.
Möckel M; Koehler K; Anker SD; Vollert J; Moeller V; Koehler M; Gehrig S; Wiemer JC; von Haehling S; Koehler F
Eur J Heart Fail; 2019 Nov; 21(11):1445-1458. PubMed ID: 31129929
[TBL] [Abstract][Full Text] [Related]
29. Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.
Eurlings LW; Sanders-van Wijk S; van Kraaij DJ; van Kimmenade R; Meeder JG; Kamp O; van Dieijen-Visser MP; Tijssen JG; Brunner-La Rocca HP; Pinto YM
J Card Fail; 2014 Dec; 20(12):881-90. PubMed ID: 25175696
[TBL] [Abstract][Full Text] [Related]
30. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
31. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
[TBL] [Abstract][Full Text] [Related]
32. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation.
Smith JG; Newton-Cheh C; Almgren P; Struck J; Morgenthaler NG; Bergmann A; Platonov PG; Hedblad B; Engström G; Wang TJ; Melander O
J Am Coll Cardiol; 2010 Nov; 56(21):1712-9. PubMed ID: 21070922
[TBL] [Abstract][Full Text] [Related]
33. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
Pascual-Figal DA; Hernández-Vicente A; Pastor-Pérez F; Martínez-Sellés M; Solé-González E; Alvarez-García J; García-Pavía P; Varela-Román A; Sánchez PL; Delgado JF; Noguera-Velasco JA; Bayes-Genis A;
Eur J Heart Fail; 2024 Apr; 26(4):776-784. PubMed ID: 38606524
[TBL] [Abstract][Full Text] [Related]
34. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
[TBL] [Abstract][Full Text] [Related]
35. MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.
Kolditz M; Seyfarth HJ; Wilkens H; Ewert R; Bollmann T; Dinter C; Hertel S; Klose H; Opitz C; Grünig E; Höffken G; Halank M
Lung; 2015 Dec; 193(6):901-10. PubMed ID: 26363916
[TBL] [Abstract][Full Text] [Related]
36. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
[TBL] [Abstract][Full Text] [Related]
37. The predictive value of plasma biomarkers in discharged heart failure patients: role of plasma NT-proBNP.
Leto L; Testa M; Feola M
Minerva Cardioangiol; 2016 Apr; 64(2):157-64. PubMed ID: 26373781
[TBL] [Abstract][Full Text] [Related]
38. Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation.
Staszewsky L; Meessen JMTA; Novelli D; Wienhues-Thelen UH; Disertori M; Maggioni AP; Masson S; Tognoni G; Franzosi MG; Lucci D; Latini R
BMC Cardiovasc Disord; 2021 Nov; 21(1):553. PubMed ID: 34798808
[TBL] [Abstract][Full Text] [Related]
39. Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels.
Carrasco-Sánchez FJ; Pérez-Calvo JI; Morales-Rull JL; Galisteo-Almeda L; Páez-Rubio I; Barón-Franco B; Aguayo-Canela M; Pujol-De la llave E
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):115-21. PubMed ID: 24522084
[TBL] [Abstract][Full Text] [Related]
40. Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study.
Charitakis E; Walfridsson H; Alehagen U
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
